OXYGEN Biotherapeutics Inc
has said the US Food and Drug
Administration (FDA) has lifted the
clinical hold on Oxycyte, meaning
the company can continue with the
clinical development program in the
country.
The company said it had submitted
animal studies’ results to address
FDA concerns about the use of
the drug in treating traumatic
brain injuries, and in particular the
interactions between OxyCyte and
the immune system.The above article was sent to subscribers in Pharmacy Daily's issue from 06 Mar 14 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 06 Mar 14
AUSTRALIA needs more pharmacists than ever, in the face of an ageing population and rising healthcare demands, according to the Pharmaceutical Society of Australia (PSA).
INTERN pharmacists from Monash University are set to join Victoria’s immunisation workforce under a new Secretary Approval by the Victorian Health Department.
VIRTUAL care delivered through telephone or video conference has now embedded itself as a core component of healthcare delivery in NSW, new market reports released today have revealed.
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.